ACP
PTCT icon

Acuta Capital Partners’s PTC Therapeutics PTCT Stock Holding History

Acuta Capital Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-36,000
Closed -$1.22M – 46
2019
Q3 		$1.22M Buy
+36,000
New +$1.57M 0.88% 26

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Acuta Capital Partners's PTCT Position: Q4 2019 in Review

Acuta Capital Partners sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 36,000 shares — an estimated $1.22M sold.

Acuta Capital Partners first reported a position in PTCT in Q3 2019 and held it in 1 quarter. The position peaked at $1.22M in Q3 2019. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

  • Acuta Capital Partners reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Acuta Capital Partners sold 36,000 PTC Therapeutics shares in Q4 2019, an estimated $1.22M.
  • Acuta Capital Partners first reported a position in PTC Therapeutics in Q3 2019 and held it in 1 quarter.
  • Acuta Capital Partners's PTC Therapeutics position peaked at $1.22M in Q3 2019.
  • 206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Acuta Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.